Key clinical point: Standard of care for castration-resistant prostate cancer involves androgen receptor signaling inhibitors (ARSI), but this treatment is largely ineffective because of the development of ARSI drug resistance.

Major finding: Data suggest that AR function could be stopped biochemically with antagonists that target the ligand-binding domain and biophysically with cryo electron microscopy (Cryo-EM) but more research is needed.

Study details: The data come from a review of biochemical and biophysical approaches to blocking androgen receptor activity in castration-resistant prostate cancer.

Disclosures: The study was supported by the National Institutes of Health, and by multiple DoD Idea Development grants to study authors. Lead author Dr. Asangani had no financial conflicts to disclose.